Transcripta Bio

About

Transcripta Bio is a Palo Alto, California-based AI-native drug discovery company advancing therapies for neurological and neuromuscular diseases ¹²³. Its closed-loop discovery engine uses transcriptomic signature matching to identify drugs whose molecular signatures are the inverse of patient-derived disease signatures ¹². The platform combines a Disease Signature Atlas built from patient single-cell RNA sequencing data, a Drug-Gene Atlas mapping the transcriptomic response of FDA-approved and novel compounds, and Conductor AI, a machine learning system trained on more than one billion gene responses ¹².

On 2026-07-22 Transcripta Bio announced it had raised $24M to advance IND-enabling studies across its portfolio and support clinical preparation in its Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs ¹²³. Mayo Clinic and Omnimed joined the round as new investors, alongside existing investors JAZZ Venture Partners, BlueYard Capital, and a group of life sciences family offices ¹²³. The company’s pipeline spans four programs across Myotonic Dystrophy, FSHD, ASD, and Huntington’s Disease ¹².

Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.